Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive ...

Kenvue said Monday that its board was taking steps to realize shareholder value and allow the company to “reach its full ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

Present Market Standing of Kenvue With a volume of 8,876,649, the price of KVUE is up 1.54% at $21.41. RSI indicators hint that the underlying stock may be overbought. Next earnings are expected ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Find the latest information on Kenvue Inc. Common Stock (KVUE) insider activity and insider shares traded to make sound investments with Nasdaq.com.

Kenvue Inc., a spin-off of Johnson & Johnson, has had a difficult debut in the stock market with shares down about 25% since the IPO. Recent performance by Kenvue prove that the company is a ...

Kenvue stock pays a fairly high dividend that yields 4.4%. The company is expecting modest revenue growth of around 6% this year. It will have at least some exposure to talc-related lawsuits ...

Kenvue's management presented the second quarter 2024 results on August 6, 2024. Adjusted earnings per share ("EPS") were 16% better than expected , while net sales were 1.8% ahead of expectations.

Kenvue shares are up just 7% year-to-date compared to more than 23% gains in the S&P 500. Competitors Haleon HLN and Proctor and Gamble Company PG have climbed 21% and 16%, respectively, since the ...

Kenvue (KVUE-0.23%) seems like an incredibly safe stock. It holds the rights to products that you (and probably almost everyone else you know) use on a daily basis. And, unsurprisingly, it's ...